AXQ Capital’s MBX Biosciences MBX Stock Holding History

AXQ Capital’s Portfolio MBX Stock Details MBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,463	Closed	-$204K	–	1312
2025 Q4	$204K	Buy	+6,463	New	+$157K	0.05%	564

Other funds holding MBX

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

AXQ Capital's MBX Position: Q1 2026 in Review

AXQ Capital sold out of MBX Biosciences (MBX) in Q1 2026, closing a stake of 6,463 shares — an estimated $204K sold.

AXQ Capital first reported a position in MBX in Q4 2025 and held it in 1 quarter. The position peaked at $204K in Q4 2025. 157 funds tracked by Wall St. Rank hold MBX as of Q1 2026.

AXQ Capital reported no remaining MBX Biosciences position as of Q1 2026 after selling out during the quarter.
AXQ Capital sold 6,463 MBX Biosciences shares in Q1 2026, an estimated $204K.
AXQ Capital first reported a position in MBX Biosciences in Q4 2025 and held it in 1 quarter.
AXQ Capital's MBX Biosciences position peaked at $204K in Q4 2025.
157 funds tracked by Wall St. Rank held MBX Biosciences as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.